• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci U S A . Increased receptor binding and spike glycosylation, remodeled immune escape of surging SARS-CoV-2 subvariant BA.3.2.2/RE.2.

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A

. 2026 Sep 15;123(37):e2614163123.
doi: 10.1073/pnas.2614163123. Epub 2026 Sep 8.

Increased receptor binding and spike glycosylation, remodeled immune escape of surging SARS-CoV-2 subvariant BA.3.2.2/RE.2.2/Cicada​


Linjie Li # 1 2 , Linh Nguyen # 1 , Hao Qu # 1 2 , Qile Wu 1 2 , Pengyue Gao 1 3 , Dedong Li 1 , Xinyu Li 4 , Xueyuan Liu 5 , Qiuyao Jiang 6 , Kefang Liu 7 8 , Catherine C L Wong 9 10 , George Fu Gao 1 2

Affiliations Expand


Abstract​


SARS-CoV-2 continues to evolve. The subvariant BA.3.2 (Cicada), a derivative of the Omicron BA.3 subtype first detected in late 2024, harbors multiple spike protein mutations, ORF7 and ORF8 deletions, and has recently evolved sublineages (BA.3.2.1 and BA.3.2.2), rendering it a critical target for epidemiological surveillance. The BA.3.2.2 sublineage, represented by RE.2.2, shows a marked upward trend in late 2025. Using surface plasmon resonance, we found that RE.2.2's spike (S) protein receptor-binding domain (RBD) exhibits relatively high affinity for human receptor angiotensin-converting enzyme 2, with structural analysis identifying the R493Q reverse mutation as the key determinant. Pseudovirus infection and antibody neutralization assays demonstrated that RE.2.2 exhibited a distinct neutralization profile compared to contemporaneous dominant subvariants. Notably, several antibodies that previously lacked neutralizing activity (e.g., S2K146 and L4.65) to other subvariants regained neutralizing potency against RE.2.2, which was associated with key mutations including G446D. Profiling of RE.2.2 RBD binding to ACE2 orthologs across species showed no significant difference in species tropism from the representative Omicron BA.1. Importantly, RE.2.2 exhibits the newly emerged N-linked glycosylation at spike protein N529 (absent in all other subvariants), a modification potentially associated with immune evasion or spike protein conformational dynamics. In addition, we corroborated the "O-follow-N" glycosylation observation as previously reported, where O-linked glycans preferentially localize near N-glycosylation sites, implying coordinated glycan organization as an extra layer of spike regulation. These findings illuminate the evolutionary characteristics, functional changes, and the constrained virus immune escape of BA.3.2.2 (RE.2.2), providing critical insights into antibody development and variant surveillance.

Keywords: BA.3.2.2; SARS-CoV-2; glycosylation; immune escape; receptor-binding.
 
Back
Top Bottom